Advertisement

Picture EBD Group ChinaBio Partnerting Forum 2021 651x80
Person › Details

Thorsten Schüller (CureVac AG)

Schüller, Thorsten (CureVac 201911 Corporate Communications)

 

Organisation Organisation CureVac AG
  Group CureVac (Group)
Products Product public relations / investor relations / marcom (services)
  Product 2 mRNA-based drug
     

CureVac AG. (11/20/19). "Press Release: CureVac to Present at the 31st Annual Piper Jaffray Healthcare Conference". Tübingen & Boston, MA.

CureVac AG, a clinical stage biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Chief Executive Officer, Dan Menichella, will present a corporate overview at the 31st Annual Piper Jaffray Healthcare Conference in New York on December 3, 2019.

The company will also be holding one-on-one meetings. Interested parties can contact Thomas Hoffmann (thoffmann@soleburytrout.com) to schedule a meeting with CureVac representatives during the conference.


About CureVac AG

CureVac is a leading company in the field of messenger RNA (mRNA) technology with more than 19 years of expertise in handling and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. To date, CureVac has received approximately $420 million (€400 million) in equity investments, including significant investments from SAP founder Dietmar Hopp’s dievini and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and others.

For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.


***


Media Contact

Thorsten Schüller, Corporate Communications
CureVac AG, Tübingen, Germany
T: +49 7071 9883-1577
thorsten.schueller@curevac.com

Investor Relations Contact

Thomas Hoffmann
Solebury Trout
T: +1 646-378-2931
thoffmann@soleburytrout.com

   
Record changed: 2021-02-20

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px


More documents for Thorsten Schüller


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px




» top